Currently enrolling: ARTISAN Phase 4 study to assess effect of early and rapid treprostinil therapy in mean pulmonary artery pressure (mPAP) reduction and reverse right ventricle remodeling in pulmonary arterial hypertension patients

ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And Function) is a Phase 4, Prospective, Multi-center, Single-Arm Study to assess the effect of early and rapid treprostinil therapy to reduce mean pulmonary artery pressure (mPAP, improve right ventricular (RV) function, and reverse RV remodeling, in patients with pulmonary arterial hypertension (PAH). Estimated enrolment is 50 persons, in 25 sites in the US. The sponsor is United Therapeutics.

Source: Pulmonary Vascular Research Institute (PVRI) website, News section, May 24, 2023, at this link

For full details of the study consult the dedicated page on the website

Scroll to Top